B8F Share Price

Open 3.38 Change Price %
High 3.40 1 Day -0.03 -0.91
Low 3.25 1 Week -0.13 -3.82
Close 3.27 1 Month 0.29 9.73
Volume 43901 1 Year 1.30 65.99
52 Week High 3.70
52 Week Low 1.71
B8F Important Levels
Resistance 2 3.41
Resistance 1 3.35
Pivot 3.31
Support 1 3.19
Support 2 3.13
ETR Germany Most Active Stocks
CBK 7.27 3.56%
CBK 7.27 3.56%
DBK 17.44 5.76%
DBK 17.44 5.76%
EOAN 6.46 0.31%
EOAN 6.46 0.31%
DTE 15.29 1.53%
DTE 15.29 1.53%
DTE 15.29 1.53%
DTE 15.29 1.53%
More..
ETR Germany Top Gainers Stocks
S9H 0.16 45.45%
VG8 6.30 21.15%
BCY2 10.91 16.93%
5M71 39.00 13.70%
CUR 1.09 13.54%
CUR 1.09 13.54%
CUR 1.09 13.54%
I7N 0.52 13.04%
BPG 0.33 10.00%
BPG 0.33 10.00%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
M6YA 0.84 -60.00%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
E8X 0.25 -32.43%
GRF 0.80 -9.09%
GRF 0.80 -9.09%
GRF 0.80 -9.09%
More..

Biofrontera AG (ETR: B8F)

B8F Technical Analysis 3
As on 7th Dec 2016 B8F Share Price closed @ 3.27 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.74 & Buy for SHORT-TERM with Stoploss of 3.05 we also expect STOCK to react on Following IMPORTANT LEVELS.
B8F Target for December
1st Target up-side 3.77
2nd Target up-side 4.03
3rd Target up-side 4.29
1st Target down-side 3.03
2nd Target down-side 2.77
3rd Target down-side 2.51
B8F Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.biofrontera.com
B8F Address
B8F
Hemmelrather Weg 201
Leverkusen, 51377
Germany
Phone: 49 214 87 63 2 10
Fax: 49 214 87 63 2 90
B8F Latest News
Interactive Technical Analysis Chart Biofrontera AG ( B8F ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biofrontera AG
B8F Business Profile
Biofrontera AG, a biopharmaceutical company, engages in the development of drugs and medicinal cosmetics for the treatment of skin diseases and the regenerative care of damaged skin. The company offers Ameluz drug for the treatment of actinic keratosis in the European countries. Its products also include Belixos cream for the basic care of inflamed, itchy, and flaky skin, such as in localized itching, atopic dermatitis, or psoriasis; and BF-RhodoLED, a lamp for photodynamic therapy. In addition, the company is involved in the development BF-derm1, which is in Phase II clinical trial for the treatment of chronic, antihistamine-refractory urticaria; and BF-1, a specific serotonin receptor antagonist that is in Phase I clinical trial for migraine prophylaxis. Further, it focuses on developing Ameluz for other superficial cancer and warts. The company was founded in 1997 and is headquartered in Leverkusen, Germany.